PMID- 24528219
OWN - NLM
STAT- MEDLINE
DCOM- 20150818
LR  - 20191210
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 12
DP  - 2014 Dec
TI  - Prolonged progression-free survival and preserved quality of life in the Canadian 
      prospective study of tositumomab and iodine(131)-tositumomab for previously 
      treated, rituximab-exposed, indolent non-Hodgkin lymphoma.
PG  - 2754-60
LID - 10.3109/10428194.2014.894190 [doi]
AB  - Radioimmunotherapy offers a unique treatment modality for indolent non-Hodgkin 
      lymphoma (iNHL). We report 5-year outcomes and quality of life (QoL) in 
      tositumomab and iodine(131)-tositumomab (TST/I(131)-TST) treated patients with 
      iNHL previously treated with rituximab. Ninety-three patients with >/= 2 lines of 
      therapy, responding to last treatment, were enrolled at 12 Canadian centers. 
      Median age, disease duration and number of prior therapies (#PTx) were 59 years, 
      4.9 years and 5, respectively. Outcomes were response rate (43.0%), median 
      progression-free survival (mPFS) (12.0 months), 5-year PFS (27%) and median 
      overall survival (OS) (59.8 months). In responders, median response duration and 
      mPFS were not reached. Improvements in QoL were seen by week 7. In univariate and 
      multivariate analyses, hemoglobin, disease bulk and body surface area (BSA) 
      predicted OS, whereas lactate dehydrogenase (LDH), bulk, BSA and #PTx predicted 
      PFS. Most common adverse events (AEs) were fatigue and nausea. Two cases of 
      myelodysplastic syndrome (MDS) were reported. TST/I(131)-TST was associated with 
      durable responses, and prolonged OS and PFS in heavily pretreated iNHL.
FAU - Olney, Harold J
AU  - Olney HJ
AD  - Centre Hospitalier de l'Universite de Montreal , Montreal , Canada.
FAU - Freeman, Marni A
AU  - Freeman MA
FAU - Stewart, Douglas A
AU  - Stewart DA
FAU - Mangel, Joy E
AU  - Mangel JE
FAU - White, Darrell J
AU  - White DJ
FAU - Elia-Pacitti, Julia O
AU  - Elia-Pacitti JO
LA  - eng
SI  - ClinicalTrials.gov/NCT00240565
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140403
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - K1KT5M40JC (tositumomab I-131)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Canada
MH  - Female
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/diagnosis/*mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Radioimmunotherapy
MH  - Retreatment
MH  - Rituximab
MH  - Treatment Outcome
MH  - Tumor Burden
OTO - NOTNLM
OT  - Indolent NHL
OT  - durable response
OT  - quality of life
OT  - radioimmunotherapy
OT  - tositumomab
EDAT- 2014/02/18 06:00
MHDA- 2015/08/19 06:00
CRDT- 2014/02/18 06:00
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2015/08/19 06:00 [medline]
AID - 10.3109/10428194.2014.894190 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Dec;55(12):2754-60. doi: 10.3109/10428194.2014.894190. Epub 
      2014 Apr 3.